The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?

Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer. Bevacizumab has demonstrated a gain in progression-free survival and a trend towards an overall survival benefit in v...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruse, Vibeke, Denys, Hannelore, Van Den Broecke, Rudy, Van Belle, Simon, Cocquyt, Veronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing AG 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661078/
https://www.ncbi.nlm.nih.gov/pubmed/23710429
http://dx.doi.org/10.1186/2193-1801-2-202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661078/
https://www.ncbi.nlm.nih.gov/pubmed/23710429
http://dx.doi.org/10.1186/2193-1801-2-202

Ejemplares similares